The perils of inhibiting deficient factors

1Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

Abstract

Essentials Anticoagulation in patients with factor X deficiency is an evidence-poor area. A patient with factor X deficiency was anticoagulated with warfarin followed by rivaroxaban. Warfarin may be a safer anticoagulant option than rivaroxaban in hereditary factor X deficiency. A baseline coagulation screen should be performed prior to commencement of anticoagulation. Summary: We report a case of a previously undiagnosed factor X deficiency in an 83-year-old man who had no previous bleeding history despite multiple hemostatic challenges. He was anticoagulated with warfarin for atrial fibrillation without bleeding complications; however, major hemorrhage occurred soon after a switch to rivaroxaban.

Cite

CITATION STYLE

APA

Sayar, Z., Speed, V., Patel, J. P., Patel, R. K., & Arya, R. (2018). The perils of inhibiting deficient factors. Journal of Thrombosis and Haemostasis, 16(8), 1535–1536. https://doi.org/10.1111/jth.14195

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free